Roberto's
Leadman is a Beijing-based in vitro diagnostics company that develops, manufactures, and sells clinical chemistry reagents, chemiluminescence immunoassay analyzers, and biochemical analyzers to hospital laboratories and distributors across China and selected international markets.
- Company typePublic
- Founded1997
- HeadquartersBeijing, China
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Roberto's firmographics
Firmographics- Name
- Roberto's
- Legal name
- 北京爱游戏官网入口_爱游戏中国生化技术有限公司
- Website
- https://robertopizzeria.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Leadman is a Beijing-based in vitro diagnostics company that develops, manufactures, and sells clinical chemistry reagents, chemiluminescence immunoassay analyzers, and biochemical analyzers to hospital laboratories and distributors across China and selected international markets.
- Ownership category
- akta.pro rank
Roberto's industry classification
Industry- Product category
- In Vitro Diagnostics (IVD)
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071)
- akta.pro primary industry
- IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)
- akta.pro secondary industries
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where Roberto's is headquartered
LocationHeadquarters
- HQ city
- Beijing
- HQ country
- China
- HQ region
- Asia
Offices8 records
Markets served
Roberto's business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- 体外诊断试剂销售: 爱游戏官网入口_爱游戏中国 generates revenue primarily from the sale of in vitro diagnostic reagents including biochemical reagents, immunodiagnostic (chemiluminescence) reagents, and molecular diagnostic products. Products are sold to hospitals, clinical laboratories, and distributors across China.
- 诊断仪器销售与技术支持: Sale of self-developed diagnostic instruments including the CI1000全自动化学发光免疫分析仪 and BA800全自动生化分析仪, along with associated technical services and after-sales support.
- 诊断仪器销售: Self-developed automated chemiluminescence immunoassay analyzer CI1000 has been successfully sold after its market launch at CMEF.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Roberto's product offering
Product offeringCore offering
Roberto's (Leadman) manufactures and sells in vitro diagnostic reagents — including biochemical diagnostic reagents and immunodiagnostic (chemiluminescence) reagents — together with self-developed clinical analyzers such as the CI1000 fully automated chemiluminescence immunoassay analyzer and BA800 fully automated biochemical analyzer. Products are sold to hospitals, clinical laboratories, and regional distributors for clinical testing of tumor markers, hormones, infectious diseases, cardiac markers, and routine biochemistry panels.
Product overview
爱游戏官网入口_爱游戏中国 (Roberto's/Leadman) is a vertically integrated in vitro diagnostics (IVD) company offering a portfolio of diagnostic reagents and laboratory instruments. The product portfolio consists of the main 爱游戏官网入口_爱游戏中国 brand (covering biochemical diagnostic reagents), a 诊断试剂 (diagnostic reagents) product line spanning biochemical and immunoassay reagents for tumor markers, hormones, and infectious diseases, and a 实验仪器 (laboratory instruments) line featuring the self-developed CI1000全自动化学发光免疫分析仪 (automated chemiluminescence immunoassay analyzer) and BA800全自动生化分析仪 (automated biochemical analyzer). Subsidiary brands include 德赛诊断系统 (Shanghai) and 北京阿匹斯生物技术有限公司. The company also operates a fully automated reagent production line with four digital modules (配制, 灌装, 贴标, 包装). Products serve clinical laboratories across tumor markers, hormones, infectious diseases, cardiac markers, and metabolic testing.
Differentiator
Problem solved
Functional benefit
Brands
- CI1000: Self-developed Fully Automated Chemiluminescence Immunoassay Analyzer for tumor markers, hormones, infectious disease detection
Products and services
- Biochemical Diagnostic Reagents (诊断试剂) Biochemical reagent product line for clinical chemistry testing, sold to hospital clinical laboratories and diagnostic testing centers. Covers routine biochemistry panels and metabolic testing.
- Leadman Immunoassay Reagents (爱游戏官网入口_爱游戏中国 immunodiagnostic/chemiluminescence reagents) Chemiluminescence-based immunodiagnostic reagents for tumor marker, hormone, and infectious disease detection, sold to hospital clinical laboratories for use with the CI1000 analyzer.
- CI1000 Fully Automated Chemiluminescence Immunoassay Analyzer Self-developed fully automated chemiluminescence immunoassay analyzer with magnetic particle-based detection, supporting tumor marker, hormone, and infectious disease detection. Throughput up to 180+ tests/hour, wide linear range, ultra-low background interference. Sold to hospital clinical laboratories.
- BA800 Fully Automated Biochemical Analyzer (BA800全自动生化分析仪) Self-developed fully automated biochemical analyzer for clinical chemistry testing, sold to hospital clinical laboratories.
- IDS Fully Automated Biochemical Immunoassay Analyzer (IDS全自动生化免疫分析仪) Fully automated biochemical immunoassay analyzer co-developed with UK-based IDS (Immunodiagnostic Systems plc), obtained medical device registration certificate in 2014. Sold to hospital clinical laboratories.
- Desai Diagnostic Systems Reagents and Instruments (德赛诊断) Diagnostic reagents and instruments sold under the Desai subsidiary brand, providing additional immunodiagnostic and clinical chemistry products for hospital clinical laboratories.
- Beijing Apis Biotechnology Molecular Diagnostics Products (北京阿匹斯生物技术) Wholly-owned subsidiary specializing in molecular diagnostics products, including COVID-19 detection products (CE certified in 2020) and other molecular diagnostics solutions. Sold to hospital and clinical laboratories.
Quantifiable outcome
- 全自动化学发光免疫分析仪CI1000 — 最高180+ tests/hour, 百万级宽线性范围, 超微量灵敏度, 背景干扰接近零值
- +3 more outcomes
Companies that use Roberto's
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Roberto's technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Roberto's partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- 苏州立禾生物core爱游戏官网入口_爱游戏中国 and Suzhou Lihe Bio formally signed a strategic cooperation agreement to jointly develop and expand the IVD market, leveraging complementary product portfolios and market channels.
- 俄罗斯VT公司 (Russia VT Company)core爱游戏官网入口_爱游戏中国 and Russian VT Company reached a strategic cooperation to jointly develop overseas market layout and construction, expanding international presence in the Russian market.
- 高博医疗集团core爱游戏官网入口_爱游戏中国 and Gaobo Medical Group established a strategic partnership to jointly build a high-level scientific and technological innovation platform, combining clinical research capabilities with diagnostic product development.
- 润达医疗core爱游戏官网入口_爱游戏中国 and Runda Medical reached a strategic cooperation to leverage Runda's IVD distribution network and supply chain capabilities in the Chinese hospital market.
- 奥森多 (Ortho Clinical Diagnostics / DiaSorin)core爱游戏官网入口_爱游戏中国 and Ortho Clinical Diagnostics launched the MPA project (collaborative development/marketing of immunodiagnostic products), representing a strategic technology and go-to-market partnership.
- Enigma诊断 (Enigma Diagnostics)core爱游戏官网入口_爱游戏中国 partnered with Enigma Diagnostics to enter the molecular diagnostics sector, expanding from biochemical and immunoassay diagnostics into the rapidly growing molecular diagnostics market.
- 德赛诊断系统 (Desai Diagnostic Systems)core爱游戏官网入口_爱游戏中国 partnered with international diagnostics giant 德赛诊断 (Desai), acquiring a controlling stake to expand product line and enhance market share in the Chinese IVD market. 德赛诊断系统（上海）有限公司 became a subsidiary of 爱游戏官网入口_爱游戏中国.
- IDS (Immunodiagnostic Systems holding plc)core爱游戏官网入口_爱游戏中国 signed a co-development contract with UK-based IDS (Immunodiagnostic Systems holding plc) to jointly develop diagnostic reagents for the Chinese market. IDS全自动生化免疫分析仪 obtained medical device registration certificate.
- 北京经济技术开发区诊断试剂创新联盟minor爱游戏官网入口_爱游戏中国 participated in the creation of the Beijing Economic Development Zone Diagnostic Reagent Innovation Alliance, serving as a council member unit and taking responsibility for organizing and coordinating alliance activities.
- 德赛诊断系统（上海）有限公司coreSubsidiary of 爱游戏官网入口_爱游戏中国 acquired through acquisition of a controlling stake in 德赛诊断系统（上海）有限公司. Focuses on immunodiagnostic systems and maintains a research collaboration with Shanghai Tongren Hospital.
- 克林顿健康拓展行动 (CHAI / Clinton Health Access Initiative)minor爱游戏官网入口_爱游戏中国, as council member of the Beijing Economic Development Zone IVD Innovation Alliance, helped organize the Clinton Health Access Initiative seminar connecting Chinese IVD manufacturers with CHAI's procurement network for Africa and developing countries.
Scale indicators6 records
Recent moves12 records
Expansion highlights5 records
Roberto's competitors and assessment
Company assessmentEmerging players
- Da An Gene (达安基因): Chinese molecular diagnostics specialist and IVD reagent provider with strong PCR and clinical testing capabilities. Comparable to Leadman's expansion into molecular diagnostics via the Enigma partnership and Beijing Apis subsidiary.
- Runda Medical (润达医疗): Chinese IVD distributor and channel partner; Leadman's 2021 strategic partner. Overlaps in IVD distribution and channel services, with growing proprietary reagent manufacturing — a partial overlap with Leadman's product strategy.
Broad incumbents
- Mindray Medical (迈瑞医疗): China's largest medical device and IVD company, offering a comprehensive IVD platform including chemiluminescence immunoassay, biochemistry, hematology, and molecular diagnostics. Directly competes with Leadman's CI1000 and biochemical analyzer offerings in similar hospital segments.
- Roche Diagnostics: Global IVD market leader with the cobas immunoassay and clinical chemistry platforms. Dominant competitor in tier-3 Chinese hospitals and the standard against which Leadman's CI1000 and BA800 must benchmark.
- KingMed Diagnostics (金域医学): China's leading third-party medical laboratory network with strong reference laboratory and specialty testing capabilities. Comparable to Leadman's CNAS-accredited reference laboratory service business and potential customer in the same hospital channel.
- Ortho Clinical Diagnostics (QuidelOrtho): Multinational IVD company and Leadman's strategic technology partner (MPA project, 2017/2019). Comparable in immunoassay focus and shares distribution channels with Leadman in selected Chinese hospital accounts.
Direct peers
- Yhlo Biotech (亚辉龙): Chinese IVD company with strong focus on chemiluminescence immunoassay and autoimmune/infectious disease diagnostics. Direct competitor in tier-2 and tier-3 hospital segments where Leadman has historically concentrated.
- Autobio Diagnostics (安图生物): Chinese IVD company specializing in immunoassay (chemiluminescence), microbiology, and clinical chemistry reagents with proprietary automated analyzers. Head-to-head competitor with Leadman in immunology and biochemistry segments across Chinese hospital laboratories.
- Snibe Diagnostic (新产业生物): Leading Chinese chemiluminescence immunoassay (CLIA) specialist with globally installed MAGLUMI series analyzers. Direct competitor to Leadman's CI1000 in tumor markers, hormones, and infectious disease panels.
- Maccura Biotechnology (迈克生物): China-based IVD manufacturer with a similar full-stack product portfolio spanning clinical chemistry, immunoassay, hematology, and rapid diagnostics. Comparable scale and channel structure to Leadman, with overlapping target hospital segments.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Roberto's social profiles
Digital presenceRoberto's compliance and trust
Trust signalCompliance6 records
Roberto's financial estimates
Financial estimateRevenue estimate
Valuation estimate
Roberto's leadership team
Management profileNumber of profiles
Profiles10 records
Roberto's subsidiaries and ownership
Company hierarchySubsidiaries2 records
Roberto's funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Roberto's M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Roberto's
What does Roberto's do?
Roberto's (Leadman) manufactures and sells in vitro diagnostic reagents — including biochemical diagnostic reagents and immunodiagnostic (chemiluminescence) reagents — together with self-developed clinical analyzers such as the CI1000 fully automated chemiluminescence immunoassay analyzer and BA800 fully automated biochemical analyzer. Products are sold to hospitals, clinical laboratories, and regional distributors for clinical testing of tumor markers, hormones, infectious diseases, cardiac markers, and routine biochemistry panels.
Is Roberto's a public or private company?
Roberto's is a public company. It is classified as public and is currently operating.
When was Roberto's founded?
Roberto's was founded in 1997. It employs 101 to 250 people.
Where is Roberto's based?
Roberto's is headquartered in Beijing, China, in the Asia region.
How does Roberto's make money?
Three revenue lines are on record. 体外诊断试剂销售 is the primary driver. The others are 诊断仪器销售与技术支持 and 诊断仪器销售.
Who are Roberto's's main competitors?
Emerging players on record are Da An Gene (达安基因) and Runda Medical (润达医疗). Broad incumbents are Mindray Medical (迈瑞医疗), Roche Diagnostics, KingMed Diagnostics (金域医学) and Ortho Clinical Diagnostics (QuidelOrtho). Direct peers are Yhlo Biotech (亚辉龙), Autobio Diagnostics (安图生物), Snibe Diagnostic (新产业生物) and Maccura Biotechnology (迈克生物).
Does Roberto's have an API?
No public API is recorded for Roberto's.
What industry is Roberto's in?
Roberto's's product category is In Vitro Diagnostics (IVD). Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 325413 and its SIC code is 2835.